Sichenzia Ross Ference LLP Represents Aegis Capital Corp. in $7.25 Million Initial Public Offering of Greenwich LifeSciences, Inc.
Press Release – New York, NY – September 29, 2020 – Sichenzia Ross Ference LLP today announced that it represented Aegis Capital Corp., as a sole bookrunner in the initial public offering of 1,260,870 shares of the common stock of Greenwich LifeSciences, Inc. (NASDAQ: GSLI), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. The shares were sold to the public at at a price of $5.75 per share for gross proceeds of approximately $7,250,000.
The shares commenced trading on The Nasdaq Capital Market on September 25, 2020.
The Sichenzia Ross Ference LLP team was led by Partners Gregory Sichenzia, Darrin Ocasio, and Avital Perlman, counsel Jeff Cahlon and associate Yian Pan.
- Sichenzia Ross Ference LLP Represents High Tide Inc. in the $20.64 million acquisition of Fab Nutrition, LLC - May 11, 2021
- Sichenzia Ross Ference LLP Represents Aegis Capital in $48.3 Million Underwritten Public Offering of Farmmi, Inc. - May 3, 2021
- Sichenzia Ross Ference LLP Wins Appeal Before the Second Circuit in a Lawsuit Brought By Investors in Connection with a Private Placement - April 30, 2021